ALANNA KAVANAUGH: Open Payments
NPI 1912448937 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,460 in 28 payments from 14 companies in 2025. Trend: 2023 $1,437 · 2024 $8,073 · 2025 $4,460
Food & beverage: $3,035Consulting: $1,200Travel & lodging: $225
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $1,355 |
| AstraZeneca Pharmaceuticals LP | 7 | $921 |
| GENZYME CORPORATION | 3 | $425 |
| Otsuka America Pharmaceutical, Inc. | 3 | $400 |
| United Therapeutics Corporation | 3 | $243 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $150 |
| Madrigal Pharmaceuticals | 1 | $150 |
| Novartis Pharmaceuticals Corporation | 1 | $140 |
| E.R. Squibb & Sons, L.L.C. | 1 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
Products named: BREZTRI, DUPIXENT, ABILIFY MAINTENA, IMFINZI, FASENRA, REZDIFFRA, COBENFY, JARDIANCE.
Industry payments across NY — which companies pay providers there.
